Ask AI
ProCE Banner Events

Redefining the Treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC) | ZYNYZ® (retifanlimab-dlwr) The First and Only FDA-Approved PD-1 Inhibitor for Adults with Inoperable Locally Recurrent or Metastatic SCAC

Key Takeaways:

  • Describe the ZYNYZ indications and NCCN Guidelines recommendation
  • Review Squamous Cell Carcinoma of the Anal Canal (SCAC); including epidemiology, incidence, and risk factors
  • Review the clinical efficacy and safety data from the POD1UM-303 trial, including progression free survival (PFS), overall survival (ORR), and the safety profile for ZYNYZ

This event has expired. No longer available for credits.

Time and location

Wednesday, July 02, 2025

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Incyte